Login / Signup

PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.

Anneke M WestermannPetronella OttevangerAn ReynersJudith R KroepMartijn G H Van OijenRoy I LalisangPetronella O Witteveen
Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Pazopanib met its primary endpoint of 3 months' progression-free survival in advanced endometrial cancer (63.3%), but response rates were modest. There may be a correlation for rare but severe gastrointestinal toxicity with previous treatments and/or disease site that has yet to be elucidated.
Keyphrases